Research Topics
| B J AnsellSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education ProgramB J Ansell
Division of General Internal Medicine Health Services Research, University of California, Los Angeles, School of Medicine, 90095, USA
JAMA 282:2051-7. 1999....- Not getting to goal: the clinical costs of noncomplianceBenjamin J Ansell
The David Geffen School of Medicine at UCLA, UCLA School of Medicine, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
J Manag Care Pharm 14:9-15. 2008..Despite overwhelming evidence in favor of statin use for lowering low-density lipoprotein cholesterol (LDL-C), medication compliance to these agents remains suboptimal, as it does in other disease states... - Hyperlipidaemia and cardiovascular diseaseBenjamin J Ansell
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Curr Opin Lipidol 19:433-4. 2008 - Targeting the anti-inflammatory effects of high-density lipoproteinBenjamin J Ansell
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA
Am J Cardiol 100:n3-9. 2007..In the future, characterizing and targeting functional aspects of HDLs may prove to offer therapeutic advantages over current treatment strategies... - The paradox of dysfunctional high-density lipoproteinBenjamin J Ansell
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
Curr Opin Lipidol 18:427-34. 2007..This review addresses how, in atherosclerosis or systemic inflammation, HDL can lose its usual atheroprotective characteristics and even paradoxically assume proinflammatory properties... - Modifying the anti-inflammatory effects of high-density lipoproteinBenjamin J Ansell
Department of Medicine, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
Curr Atheroscler Rep 9:57-63. 2007..Treatment with statins and/or apolipoprotein A1 mimetic peptides improves HDL's anti-inflammatory functions, and these as well as other medications may represent a novel pathway through which to target atherosclerosis... - High-density lipoprotein: is it always atheroprotective?Benjamin J Ansell
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA
Curr Atheroscler Rep 8:405-11. 2006..The presence of proinflammatory HDL coincides with conditions associated with chronic systemic inflammation, including atherosclerosis... - A review of trials evaluating nonstatin lipid-lowering therapiesBenjamin J Ansell
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Curr Atheroscler Rep 11:64-6. 2009..Clinical trials currently in progress will more clearly delineate the cardiovascular effects of adding either ezetimibe or extended-release niacin/laropiprant to statin therapy... - Evidence for a combined approach to the management of hypertension and dyslipidemiaBenjamin J Ansell
Cholesterol Hypertension and Atherosclerosis Management Program, University of California Los Angeles, 200 UCLA Medical Plaza, Los Angeles, CA 90095, USA
Am J Hypertens 18:1249-57. 2005..Furthermore, recent clinical trials, including those assessing atherosclerotic progression and CVD endpoints, have demonstrated the effectiveness of interventions targeted at multiple risk factors for CVD... - Rationale for combination therapy with statin drugs in the treatment of dyslipidemiaBenjamin J Ansell
Division of General Internal Medicine Cardiology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
Curr Atheroscler Rep 7:29-33. 2005..More recently, however, it has been recognized that the potential complications of this combination are far outweighed by the clinical benefits that are possible... - Developing a clinical strategy for cholesterol management in an era of unanswered questionsB J Ansell
Center for Primary Care Based Cardiovascular Disease Prevention, Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles School of Medicine, USA
Am J Cardiol 88:25F-30F. 2001..In the interim, a clinical strategy incorporating the lessons of recent clinical evidence is suggested... - Anti-inflammatory properties of HDLBenjamin J Ansell
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Rev Endocr Metab Disord 5:351-8. 2004 - Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatmentBenjamin J Ansell
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095-1679, USA
Circulation 108:2751-6. 2003..Similar results were obtained with the cell-free assay. CONCLUSIONS: The inflammatory/antiinflammatory properties of HDL distinguished patients from control subjects better than HDL cholesterol and were improved with simvastatin... - Mechanisms of disease: proatherogenic HDL--an evolving fieldMohamad Navab
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1679, USA
Nat Clin Pract Endocrinol Metab 2:504-11. 2006..The quality and function of HDL are also attractive targets for emerging therapies... - Apolipoprotein A-I mimetic peptidesMohamad Navab
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095 1679, USA
Arterioscler Thromb Vasc Biol 25:1325-31. 2005..However, understanding these physical-chemical properties provides an explanation for the mechanism of action of the active peptides... - The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDLMohamad Navab
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
J Lipid Res 45:993-1007. 2004..Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides may both promote a reduction in oxidized lipids and enhance reverse cholesterol transport and therefore may have therapeutic potential... - Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritisBevra H Hahn
Division of Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
Arthritis Res Ther 10:213. 2008.... - The double jeopardy of HDLMohamad Navab
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1679, USA
Ann Med 37:173-8. 2005..Thus, HDL structure and function may be more important than HDL-cholesterol levels in predicting risk for cardiovascular disease... - Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot studyChristina Charles-Schoeman
Division of Rheumatology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, California 90095 1670, USA
J Rheumatol 34:1459-64. 2007..We examined the effects of atorvastatin 80 mg daily on the inflammatory properties of HDL and clinical disease activity in RA... - The two faces of the 'good' cholesterolBenjamin J Ansell
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Cleve Clin J Med 74:697-700, 703-5. 2007..Thus, the functional properties of HDL--not simply the level--may need to be considered and optimized... - High-density lipoprotein function recent advancesBenjamin J Ansell
Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
J Am Coll Cardiol 46:1792-8. 2005..Functional characterization of HDL is a promising method for enhanced assessment of cardiovascular risk and effectiveness of risk reduction... - hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigationBenjamin J Ansell
Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
Heart Dis 5:2-7. 2003..The correlation between the reductions in CRP and LDL cholesterol differs from the findings of other published studies, and should prompt further investigation of the mechanism by which statins reduce CRP... - Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national surveyBenjamin J Ansell
University of California at Los Angeles, Los Angeles, CA, USA
Am Heart J 152:976-81. 2006..CONCLUSIONS: Female sex was associated with lower likelihood of LDL-C goal achievement among patients with CHD + CHD RE. This relationship remained significant after adjustment for other significant predictors of treatment success... - HDL function as a target of lipid-modifying therapyKarol E Watson
Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Rev Cardiovasc Med 8:1-8. 2007..However, an increase in HDL-C did not lead to a decrease in cardiovascular events in all trials... - Managing borderline levels of risk for coronary heart disease: two illustrative case presentationsB J Ansell
Division of General Internal Medicine and Health Services Research, UCLA Center for Primary Care-Based Cardiovascular Disease Prevention, UCLA School of Medicine, Los Angeles, Calif, USA
J Am Osteopath Assoc 101:S12-6. 2001.... - Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year laterBenjamin J Ansell
Am J Cardiol 90:524-5. 2002 - High-density lipoprotein as a therapeutic target: a systematic reviewInder M Singh
Department of Cardiovascular Medicine, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, USA
JAMA 298:786-98. 2007..High-density lipoprotein cholesterol (HDL-C) is a cardiovascular risk factor that is gaining substantial interest as a therapeutic target... - Improvement in current approaches to lipid loweringBenjamin J Ansell
Am Fam Physician 65:783, 786-7. 2002 - Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsMichael H Davidson
Radiant Development, Chicago, Illinois, USA
Am J Cardiol 96:556-63. 2005..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...